Emergent in active discussions with U.S. government for multi-year supply of BioThrax to the SNS

Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. government has indicated its intention to award Emergent a sole source contract (RFP-2011-N-13414) for the purchase of 44.75 million doses of BioThrax^® (Anthrax Vaccine Adsorbed) for inclusion in the Strategic National Stockpile (SNS) over a 5 year period. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection. Emergent anticipates finalizing a contract with the U.S. government during the third quarter of 2011.

“Emergent is pleased to be in active discussions with the U.S. government for a multi-year supply of BioThrax to the SNS”

"Emergent is pleased to be in active discussions with the U.S. government for a multi-year supply of BioThrax to the SNS," said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. "We remain dedicated to serve as a reliable and long-standing supplier of medical countermeasures that support the U.S. government's continued commitment to anthrax preparedness."